title: [Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer].
abstract: We investigated the relationship between delayed emesis caused by cisplatin (CDDP) based chemotherapy and plasma levels of serotonin, 5-hydroxy-indoleacetic acid (5-HIAA), and substance P in two patients with small cell lung cancer. In each of the cases, we used the 5-HT3 receptor antagonist ramosetron every morning on day 1-4 of the chemotherapy. In case 1, plasma levels of serotonin were low, whereas substance P levels increased since 24 hours after the injection of CDDP. The increase in substance P levels paralleled the onset of vomiting. In this case, however, substance P levels decreased and yet vomiting occurred. Similarly, in case 2, plasma levels of serotonin were low, whereas substance P levels increased since 24 hours. The increase in plasma levels of substance P and the onset of vomiting were observed at the same time 2-3 days after cisplatin administration. In this case, however, vomiting was not observed during the 5 days when the substance P was highest. Therefore, we suggested that substance P was closely associated with CDDP-induced delayed emesis, though some chemical mediators other than substance P might also be related to the emesis.
authors: Third Dept. of Internal Medicine, Faculty of Medicine, Tottori University.
authors: S
authors: S
authors: Matsumoto
authors: Y
authors: Y
authors: Kawasaki
authors: M
authors: M
authors: Mikami
authors: M
authors: M
authors: Nakamoto
authors: H
authors: H
authors: Tokuyasu
authors: Y
authors: Y
authors: Kometani
authors: H
authors: H
authors: Chikumi
authors: Y
authors: Y
authors: Hitsuda
authors: Y
authors: Y
authors: Matsumoto
authors: T
authors: T
authors: Sasaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy; D008297:Male; D012701:Serotonin / Q000097:blood; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013373:Substance P / Q000097:blood / Q000502:physiology*; D014840:Vomiting, Anticipatory / Q000209:etiology*
chemical_list: D001562:Benzimidazoles; D012702:Serotonin Antagonists; D012701:Serotonin; D013373:Substance P; D006897:Hydroxyindoleacetic Acid; C071315:ramosetron; D002945:Cisplatin